ATP Formation and Oxidative Phosphorylation

ATP Formation and Oxidative Phosphorylation

Introduction

This lecture covers ATP formation, focusing on substrate-level phosphorylation and oxidative phosphorylation. Key topics include the electron transport chain (ETC), ATP synthase, P:O ratios, and the effects of uncouplers and inhibitors.

Objectives

Upon completion of this lecture, you should be able to:

  • Define substrate-level phosphorylation and provide examples.

  • Relate mitochondrial structure to oxidative phosphorylation function.

  • Connect coenzyme reduction during catabolism to ATP production.

  • Describe ETC components and their functions.

  • Explain how the proton gradient across the inner mitochondrial membrane (IMM) drives ATP synthesis.

  • Use ETC and ATP synthase functions to explain P:O ratios of different substrates.

  • Use oxygen electrode traces to identify ETC inhibitors and uncouplers.

  • Understand the biochemical basis of non-shivering thermogenesis.

ATP: The Energy Currency

ATP (adenosine triphosphate) is a nucleoside triphosphate consisting of:

  1. Adenine

  2. Ribose

  3. Three phosphate groups

ATP supplies energy and is the energy currency of the cell. Despite its small concentration, ATP is continuously consumed and regenerated at a high rate through the ADP-ATP cycle.

Oxidative Phosphorylation

Oxidative phosphorylation is the primary ATP-producing process. It involves the transfer of electrons from NADH and FADH2 to O2, ultimately forming H2O. This process releases energy used to generate ATP.

Electron Transport Chain (ETC)

  • The ETC is a sequence of enzymes and carriers located in the inner mitochondrial membrane.

  • It transports electrons from reducing equivalents (NADH and FADH2) to O2, producing H2O.

  • The movement of electrons releases energy used in ATP synthesis.

  • The ETC consists of enzyme complexes (electron carriers), which are integral membrane proteins capable of accepting and donating one or two electrons.

  • Each component accepts electrons from the preceding carrier and transfers them to the next.

Mitochondria Structure

The mitochondria consists of:

  • Outer Mitochondrial Membrane: Highly permeable.

  • Inner Mitochondrial Membrane: Highly impermeable.

  • Matrix: Low [H+][H^+].

Sources of Reduced Coenzymes

  • Glycolysis: Produces NADH in the cytosol (transported via shuttles).

  • Fatty Acid Oxidation

  • Amino Acid Oxidation

  • Citric Acid Cycle

Redox Reactions

  • Oxidation: Addition of oxygen or removal of hydrogen/electrons.

  • Reduction: Addition of electrons/hydrogen or removal of oxygen.

  • Oxidation and reduction reactions are always coupled.

  • Examples include the citric acid cycle and glycolysis, where NAD+ is reduced to NADH, and succinate dehydrogenase, where FAD is reduced to FADH2.

Electron Transport Chain and Proton Gradient

The energy released by electron transfer is used to pump protons out of the matrix, creating an H+H^+ gradient that drives ATP synthesis.

Complexes of the Electron Transport Chain

Complex I (NADH Dehydrogenase)
  • Catalyzes the oxidation of NADH + H+H^+, with the reduction of coenzyme Q:
    NADH+H++QNAD++QH2NADH + H^+ + Q \rightarrow NAD^+ + QH_2

  • Composed of NADH dehydrogenase and prosthetic groups FMN & several Fe-S centers.

  • FMN accepts 2 electrons and 2 H+H^+ from NADH + H+H^+ to form FMNH2FMNH_2.

  • FMNH2FMNH_2 donates 2 electrons to Fe-S centers.

  • Electrons pass through iron-sulfur centers and are transferred to coenzyme Q.

  • Coenzyme Q accepts 2 e- and picks up 2 H+H^+ to yield fully reduced QH2QH_2.

Complex II (Succinate Dehydrogenase)
  • Composed of succinate dehydrogenase (Krebs Cycle enzyme), FAD, and Fe-S centers.

  • Catalyzes the oxidation of FADH2FADH_2, with reduction of coenzyme Q.
    COOCCCOOCOOC=CCOOCOO^- - C - C - COO^- \rightarrow COO^- - C = C - COO^-
    HHHHH \qquad H \qquad H \qquad H
    succinate \qquad fumarate

  • FAD is reduced to FADH2FADH_2 during succinate oxidation to fumarate.

  • FADH<em>2FADH<em>2 is re-oxidized by transferring electrons through iron-sulfur centers to CoQ, yielding QH</em>2QH</em>2.

  • The QH2QH_2 product is re-oxidized via complex III.

Coenzyme Q
  • Coenzyme Q is a collecting point for hydrogen from complexes I and II.

  • Acts as a mobile component of the respiratory chain, diffusing within the inner membrane.

Complex III
  • Accepts electrons from reduced CoQ. Electrons flow through cytochrome b and c1.

  • Electrons are carried on Heme iron, oscillating between Fe3+Fe^{3+} and Fe2+Fe^{2+}.

Complex IV
  • Electrons are transported one at a time.

Chemiosmotic Model

  • Energy from oxidation is coupled to the translocation of protons (H+H^+) from the mitochondrial matrix to the inter-mitochondrial space.

  • Complexes I, III, and IV act as proton pumps.

ATP Synthase (Complex V)

  • Units of ATP synthase (F<em>1F</em>0F<em>1F</em>0) are scattered on the inner mitochondrial membrane.

P:O Ratio

The P:O ratio is defined as:

No. of ATP molecules producedNo. of Oxygen atoms consumed\frac{\text{No. of ATP molecules produced}}{\text{No. of Oxygen atoms consumed}}

  • Starting from NADH: 2.5:1

  • Starting from FADH2FADH_2: 1.5:1

  • Uncoupler: zero

Oxygen electrode traces indicate how much oxygen is required by the electron transport chain to use up all the ADP under different conditions.

Inhibitors of the Respiratory Chain

  • Complex I: Inhibited by barbiturates (Amytal) and rotenone.

  • Complex III: Inhibited by antimycin A.

  • Complex IV: Inhibited by H2SH_2S, CO, and cyanide.

  • ATP Synthase (Complex V): Inhibited by oligomycin.

  • Inhibiting ATP synthase prevents oxygen use by the ETC.

  • Inhibition of complex I allows the mitochondria to use succinate.

  • Inhibition of complex II allows the mitochondria to use malate.

Uncouplers

  • Uncouplers abolish the coupling between oxidation and phosphorylation by increasing the IMM's permeability to H+H^+.

  • H+H^+ gradient formation fails; ATP formation stops while oxidation proceeds.

  • Examples include:

    • 2,4-dinitrophenol

    • Increased endogenous compounds: bilirubin and thyroxine.

    • Thermogenin: A physiological uncoupling protein in brown adipose tissue, allowing protons to pass without going through the F<em>0F</em>1F<em>0-F</em>1 complex, releasing energy as heat.

Dinitrophenol

  • Dinitrophenol is a weak acid that can dissolve through membranes.

  • It was used to make dynamite during WW1.

  • It was previously prescribed for weight loss but banned due to significant side effects, including death.

  • It transports protons into the matrix, increasing the electron transfer rate across the ETC with little ATP production.

  • Causes a rapid increase in the consumption of metabolic fuels and oxygen.

  • The resultant increase in heat production, combined with the decrease in ATP production, can be lethal.

Adding dinitrophenol leads to the complete utilization of oxygen.

Effects of Various Compounds on Oxygen Consumption

Substrate

Addition

Effect on O2O_2 Utilization

Malate

Amytal or Rotenone

No inhibition

Succinate

Amytal or Rotenone

Inhibition

Malate

Antimycin A

Inhibition

Succinate

Antimycin A

Inhibition

Malate

Oligomycin

Slow

Succinate

Oligomycin

Slow

Malate

Potassium cyanide

Inhibition

Succinate

Potassium cyanide

Inhibition

Summary

  • ATP is produced by substrate-level phosphorylation, but most is produced by oxidative phosphorylation.

  • The electron transport chain converts energy from electron transfer to proton removal from the matrix.

  • ATP synthase couples the re-entry of protons into the matrix to ATP synthesis.

  • Electron transfer and ATP synthesis can be inhibited or uncoupled by various compounds; their effects can be observed using oxygen electrode traces.

Clinical Case 1: A 60-year-old woman with a history of diabetes presents with fatigue and difficulty in exercise. Lab results show low ATP levels in muscle cells. What is the most likely cause of her symptoms?

A. Impaired oxidative phosphorylation
B. Increased ATP consumption due to exercise
C. High levels of ADP
D. Myopathy
E. Decreased mitochondrial biogenesis

Answer: A. Impaired oxidative phosphorylation

Clinical Case 2: A patient undergoing chemotherapy experiences muscle weakness and fatigue. Blood tests reveal low levels of NADH and FADH2. What is the most probable sequence of events leading to her symptoms?

A. Reduced substrate-level phosphorylation
B. Impaired electron transport chain function
C. Decreased ATP synthase activity
D. Increased mitochondrial membrane permeability
E. Reduced coenzyme regeneration

Answer: B. Impaired electron transport chain function

Clinical Case 3: A 35-year-old man is diagnosed with a mitochondrial disorder affecting ATP synthase. He presents with muscle cramps and exercise intolerance. What metabolic process is primarily affected?

A. Glycolysis
B. Oxidative phosphorylation
C. Citric acid cycle
D. Fatty acid oxidation
E. Substrate-level phosphorylation

Answer: B. Oxidative phosphorylation

Clinical Case 4: A research study indicates that a substance acts as an uncoupler in the mitochondria. Which of the following effects would this substance have on ATP production?

A. Increase ATP synthesis
B. Decrease oxygen consumption
C. Increase electron transfer through the ETC
D. Decrease ATP production while increasing heat
E. Stabilize the proton gradient

Answer: D. Decrease ATP production while increasing heat

Clinical Case 5: A 40-year-old male presents with confusion, and lab tests show an elevated lactate level. Which metabolic pathway is most likely disrupted?

A. Glycolysis
B. Citric acid cycle
C. Oxidative phosphorylation
D. Beta-oxidation
E. Glycogenolysis

Answer: C. Oxidative phosphorylation

Clinical Case 6: A pediatric patient presents with severe hypothermia due to a mitochondrial dysfunction affecting thermogenesis. Which protein is likely impaired?

A. Cytochrome c
B. ATP synthase
C. Uncoupling protein (UCP)
D. Coenzyme Q
E. NADH dehydrogenase

Answer: C. Uncoupling protein (UCP)

Clinical Case 7: An adult patient develops headaches and dizziness after using a drug known to inhibit Complex IV of the ETC. What is the expected consequence of this drug on cellular respiration?

A. Increased ATP production
B. Increased accumulation of NADH
C. Decreased oxygen consumption
D. Enhanced fatty acid oxidation
E. Synchronous ATP synthesis

Answer: B. Increased accumulation of NADH

Clinical Case 8: A 22-year-old woman with unexplained weight loss and muscle wasting is diagnosed with a deficiency in fatty acid oxidation. Which metabolic product is likely accumulating in her muscles?

A. Acetyl-CoA
B. Lactic acid
C. Pyruvate
D. NADH
E. FADH2

Answer: A. Acetyl-CoA

Clinical Case 9: A 70-year-old man presents with severe respiratory distress. Blood analysis shows elevated proton levels due to impaired ATP synthesis. What is the underlying mechanism?

A. Mitochondrial depolarization
B. Inhibition of ATP synthase
C. Deficiency in ADP
D. Loss of proton gradient
E. Reduced oxygen delivery

Answer: D. Loss of proton gradient

Clinical Case 10: A recent study found that a specific enzyme is responsible for the re-oxidation of FADH2 in the mitochondria. Which enzyme is primarily involved in this reaction?

A. Complex I
B. Complex II
C. Complex III
D. ATP synthase
E. Cytochrome c oxidase

Answer: B. Complex II

Clinical Case 11: A middle-aged man experiments with increased energy levels after consuming supplements that enhance the electron transport chain. What is the likely mechanism of action?

A. Increased ATP yield
B. Enhanced mitochondrial biogenesis
C. Increased aerobic capacity
D. Direct enhancement of lysosomal function
E. Increased fatty acid synthesis

Answer: A. Increased ATP yield

Clinical Case 12: A patient with a history of chronic illness has become increasingly fatigued. A biopsy shows dysfunctional mitochondria with decreased number of ATP synthase complexes. What is a potential biochemical consequence?

A. Increased ATP production
B. Weakening of the cytoskeleton
C. Accumulation of metabolic waste
D. Enhanced cellular respiration
E. Upregulation of glycolysis

Answer: C. Accumulation of metabolic waste

Clinical Case 13: A 45-year-old male presents with symptoms of myocardial infarction. Lab tests reveal high levels of creatine phosphate. Which metabolic process is most likely compensating for low ATP levels?

A. Glycolysis
B. Substrate-level phosphorylation
C. Oxidative phosphorylation
D. Phosphorylating ADP
E. β-Oxidation of fatty acids

Answer: B. Substrate-level phosphorylation

Clinical Case 14: A smoker develops chronic obstructive pulmonary disease (COPD) and shows signs of reduced efficiency in ATP production. What mitochondrial complex is most likely affected?

A. Complex I
B. Complex II
C. Complex III
D. Complex IV
E. ATP synthase

Answer: D. Complex IV

Clinical Case 15: An athlete strains his leg muscles during a marathon and experiences muscle cramps. What biochemical process is likely providing ATP under these conditions?

A. Oxidative phosphorylation
B. β-Oxidation
C. Glycolysis
D. Krebs cycle
E. Gluconeogenesis

Answer: C. Glycolysis